Kimberly Loo

2.4k total citations
17 papers, 647 citations indexed

About

Kimberly Loo is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Kimberly Loo has authored 17 papers receiving a total of 647 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 9 papers in Immunology and 4 papers in Molecular Biology. Recurrent topics in Kimberly Loo's work include Cancer Immunotherapy and Biomarkers (15 papers), CAR-T cell therapy research (11 papers) and Immunotherapy and Immune Responses (9 papers). Kimberly Loo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), CAR-T cell therapy research (11 papers) and Immunotherapy and Immune Responses (9 papers). Kimberly Loo collaborates with scholars based in United States, Switzerland and Austria. Kimberly Loo's co-authors include Adil Daud, Alain P. Algazi, Katy K. Tsai, Adi Nosrati, Jimmy J. Hwang, Michael D. Rosenblum, Matthew F. Krummel, Priscila Muñoz Sandoval, Mariela Pauli and Michael Alvarado and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and British Journal of Cancer.

In The Last Decade

Kimberly Loo

17 papers receiving 641 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kimberly Loo United States 8 536 347 126 93 51 17 647
Qiu‐Xia Qu China 13 474 0.9× 466 1.3× 142 1.1× 104 1.1× 37 0.7× 33 734
Zhengguang Wang China 7 567 1.1× 665 1.9× 141 1.1× 75 0.8× 81 1.6× 18 935
Dmitrij Ostroumov Germany 5 337 0.6× 294 0.8× 137 1.1× 60 0.6× 31 0.6× 6 526
Casilda Llácer Spain 7 334 0.6× 163 0.5× 103 0.8× 77 0.8× 48 0.9× 11 477
Anna Spille Germany 6 504 0.9× 436 1.3× 64 0.5× 48 0.5× 58 1.1× 6 660
Petros Fessas United Kingdom 8 341 0.6× 141 0.4× 91 0.7× 133 1.4× 48 0.9× 14 529
Sumbal Arooj China 9 374 0.7× 309 0.9× 89 0.7× 180 1.9× 24 0.5× 12 600
Éléonore De Guillebon France 9 335 0.6× 184 0.5× 98 0.8× 116 1.2× 32 0.6× 13 462
Annegé Vledder Netherlands 4 404 0.8× 307 0.9× 139 1.1× 126 1.4× 51 1.0× 9 626
Marya Chaney United States 11 348 0.6× 223 0.6× 104 0.8× 58 0.6× 73 1.4× 59 501

Countries citing papers authored by Kimberly Loo

Since Specialization
Citations

This map shows the geographic impact of Kimberly Loo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimberly Loo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimberly Loo more than expected).

Fields of papers citing papers by Kimberly Loo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kimberly Loo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimberly Loo. The network helps show where Kimberly Loo may publish in the future.

Co-authorship network of co-authors of Kimberly Loo

This figure shows the co-authorship network connecting the top 25 collaborators of Kimberly Loo. A scholar is included among the top collaborators of Kimberly Loo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimberly Loo. Kimberly Loo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Loo, Kimberly, Katherine S. Panageas, Margaret K. Callahan, et al.. (2023). Beyond the 5‐year milestone: Long‐term survivorship of melanoma patients treated off‐trial with anti‐PD‐1. Pigment Cell & Melanoma Research. 36(3-4). 314–320. 1 indexed citations
2.
Loo, Kimberly, James W. Smithy, Michael A. Postow, & Allison Betof Warner. (2022). Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma. Frontiers in Immunology. 12. 810388–810388. 13 indexed citations
3.
Loo, Kimberly, Debra A. Goldman, Katherine S. Panageas, et al.. (2021). Characteristics and probability of survival for patients with advanced melanoma who live five or more years after initial treatment with immune checkpoint blockade (ICB).. Journal of Clinical Oncology. 39(15_suppl). 9534–9534. 5 indexed citations
4.
Jutagir, Devika R., Adriana Espinosa, Kimberly Loo, et al.. (2021). Disparities in the use of checkpoint inhibitors and CAR T-cell therapy: A systematic review.. Journal of Clinical Oncology. 39(15_suppl). e18541–e18541. 1 indexed citations
5.
Loo, Kimberly, Tianyu Li, Hong Wu, et al.. (2020). Impact of Sun Exposure and Tanning Patterns on Next-Generation Sequencing Mutations in Melanoma. Journal of Surgical Research. 254. 147–153. 5 indexed citations
6.
Loo, Kimberly, Mengying Deng, Eric A. Ross, et al.. (2020). Primary tumor characteristics and next‐generation sequencing mutations as biomarkers for melanoma immunotherapy response. Pigment Cell & Melanoma Research. 33(6). 878–888. 4 indexed citations
7.
8.
Loo, Kimberly, Katy K. Tsai, Kelly M. Mahuron, et al.. (2017). Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight. 2(14). 56 indexed citations
9.
Nosrati, Adi, Katy K. Tsai, Simone M. Goldinger, et al.. (2017). Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. British Journal of Cancer. 116(9). 1141–1147. 98 indexed citations
10.
Loo, Kimberly, Katy K. Tsai, Mariela Pauli, et al.. (2016). Novel T cell exhaustion marker to predict monotherapy PD-1 compared to combination CTLA-4 and PD-1 response in melanoma.. Journal of Clinical Oncology. 34(15_suppl). 9520–9520. 2 indexed citations
11.
Nosrati, Adi, Simone M. Goldinger, Katy K. Tsai, et al.. (2016). Derivation and validation of a prediction scale for response to PD-1 monotherapy.. Journal of Clinical Oncology. 34(15_suppl). 9514–9514. 2 indexed citations
12.
Loo, Kimberly & Adil Daud. (2016). Emerging Biomarkers as Predictors to Anti-Pd1/PD-L1 Therapies in Advanced Melanoma. Immunotherapy. 8(7). 775–784. 21 indexed citations
13.
Daud, Adil, Kimberly Loo, Mariela Pauli, et al.. (2016). Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma. Journal of Clinical Investigation. 126(9). 3447–3452. 378 indexed citations
14.
Goldinger, Simone M., Katy K. Tsai, Paul C. Tumeh, et al.. (2016). Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanoma.. Journal of Clinical Oncology. 34(15_suppl). 9549–9549. 15 indexed citations
15.
Tsai, Katy K., Kimberly Loo, Neharika Khurana, et al.. (2015). Clinical characteristics predictive of response to pembrolizumab in advanced melanoma.. Journal of Clinical Oncology. 33(15_suppl). 9031–9031. 11 indexed citations
16.
Loo, Kimberly, Katy K. Tsai, Michael D. Rosenblum, et al.. (2015). Deep profiling of tumor immune microenvironment (TME) with fluorescence activated cell sorting (FACS) in advanced melanoma.. Journal of Clinical Oncology. 33(15_suppl). 9012–9012. 1 indexed citations
17.
Zuo, Jin, Ehsan Saadat, Kimberly Loo, et al.. (2009). Assessment of intervertebral disc degeneration with magnetic resonance single‐voxel spectroscopy. Magnetic Resonance in Medicine. 62(5). 1140–1146. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qiu‐Xia Qu Breakdown of academic impact, for papers by Zhengguang Wang Breakdown of academic impact, for papers by Dmitrij Ostroumov Breakdown of academic impact, for papers by Casilda Llácer Breakdown of academic impact, for papers by Anna Spille Breakdown of academic impact, for papers by Petros Fessas Breakdown of academic impact, for papers by Sumbal Arooj Breakdown of academic impact, for papers by Éléonore De Guillebon Breakdown of academic impact, for papers by Annegé Vledder Breakdown of academic impact, for papers by Marya Chaney
Rankless by CCL
2026